Sept 27 (Reuters) - Hoffmann-La Roche Limited
* HEALTH CANADA APPROVES TECENTRIQ® IN COMBINATION WITH CHEMOTHERAPY (NAB-PACLITAXEL) AS FIRST IMMUNOTHERAPY TREATMENT FOR AGGRESSIVE FORM OF BREAST CANCER(1)
* HOFFMANN-LA ROCHE - HEALTH CANADA APPROVED TECENTRIQ IN COMBINATION WITH CHEMOTHERAPY FOR TREATMENT OF PATIENTS WITH LOCALLY ADVANCED BREAST CANCER